Pancreas Cancer Discussion Page:
An Unmoderated Forum
*
 
Support pancreas research*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER

Pancreas Cancer

Caris > Miraca Life Sciences was posted 08/31/2012 08:03 pm by gpawelski
E-mail Address:

Message Text
And Caris was bought out by Miraca Life Sciences

Tokyo, Japan & Irving, Texas, February 3, 2012 - Caris Diagnostics, specializing in anatomic pathology services, announced a company name change to Miraca Life Sciences, Inc., following its November 2011 acquisition by Tokyo-based Miraca Holdings Inc., Japan’s largest clinical diagnostics and laboratory testing service provider. The name change, which is effective February 20, 2012, follows a successful integration process and will be reflected in all marketing and communications.

“The new name is a logical step as we complete the successful ownership transition of this world-class diagnostics organization,” said Takeo Hayashi, Chairman and CEO of the newly-named Miraca Life Sciences. “While the name has changed, the fundamental value proposition has not: a unique, high quality pathology practice with an abiding commitment to diagnostic excellence and improved patient care.”

The word “Miraca” is a combination of the Japanese words “future” and “science,” so the new corporate name is a natural fit for the company’s mission and Miraca’s global network of employees, clinicians and patients.

Miraca Life Sciences specializes in the development and commercialization of anatomic pathology services, primarily in the fields of dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company’s core team of more than 70 specialists utilize pathology laboratories currently headquartered in Irving, TX and throughout the United States.

With group net sales of ¥165.7 billion (FYE 3/2010), Miraca Holdings, a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, is engaged in the business consisting of three segments: (i) development, manufacture, and commercialization of in vitro diagnostics, (ii) clinical laboratory testing, and (iii) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc., a supplier of in vitro diagnostics in Japan, and SRL, Inc. (“SRL”), Japan’s largest commercial laboratory. SRL offers clinical laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing, including gene-based tests.

Source: Perry Street Communications

Clinical trial of molecularly-personalized chemotherapy

http://cancerfocus.org/forum/showthread.php?t=3167

Reply to this message | Return to Main Message List


Responses

No replies on file.


*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER


Pancreas Home | Surgical | Medical | Basic Sci | Docs | Registry | FAQ | Appts | Chat

Feedback | Pathology Home | Oncology Center Home | Search
Copyright © 2019 The Johns Hopkins University, Baltimore, Maryland
Last Modified: 11/11/2002 10:50 am